James S Wiley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2117723/publications.pdf

Version: 2024-02-01

113 papers	7,535 citations	53660 45 h-index	54797 84 g-index
113 all docs	113 docs citations	113 times ranked	8408 citing authors

#	Article	IF	Citations
1	Flow cytometry identifies an early stage of platelet apoptosis produced by agonists of the P2X1 and P2X7 receptors. Platelets, 2022, 33, 621-631.	1.1	5
2	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 7867.	1.8	5
3	Regulation of the Acute Sickness Response by the P2RX7 Receptor. Journal of Infectious Diseases, 2021, 224, 914-920.	1.9	4
4	Deficits in Monocyte Function in Age Related Macular Degeneration: A Novel Systemic Change Associated With the Disease. Frontiers in Medicine, 2021, 8, 634177.	1.2	10
5	Genomics of Alzheimerâ€™s disease implicates the innate and adaptive immune systems. Cellular and Molecular Life Sciences, 2021, 78, 7397-7426.	2.4	32
6	AP2RX7single nucleotide polymorphism haplotype promotes exon 7 and 8 skipping and disrupts receptor function. FASEB Journal, 2020, 34, 3884-3901.	0.2	10
7	Assays to Measure Purinoceptor Pore Dilation. Methods in Molecular Biology, 2020, 2041, 323-334.	0.4	1
8	The scavenger activity of the human P2X7 receptor differs from P2X7 pore function by insensitivity to antagonists, genetic variation and sodium concentration: Relevance to inflammatory brain diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1051-1059.	1.8	20
9	Heme Biosynthesis and Its Disorders. , 2018, , 497-513.e6.		1
10	P2X7 as a scavenger receptor for innate phagocytosis in the brain. British Journal of Pharmacology, 2018, 175, 4195-4208.	2.7	50
11	Purinergic receptorsP2RX4andP2RX7in familial multiple sclerosis. Human Mutation, 2017, 38, 736-744.	1.1	46
12	Loss of Function of P2X7 Receptor Scavenger Activity in Aging Mice. American Journal of Pathology, 2017, 187, 1670-1685.	1.9	34
13	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 377-389.	3.9	40
14	Activation of the erythroid K-Cl cotransporter Kcc1 enhances sickle cell disease pathology in a humanized mouse model. Blood, 2015, 126, 2863-2870.	0.6	21
15	P2X7 Receptors Mediate Innate Phagocytosis by Human Neural Precursor Cells and Neuroblasts. Stem Cells, 2015, 33, 526-541.	1.4	40
16	Shear stress modulates endothelial KLF2 through activation of P2X4. Purinergic Signalling, 2015, 11, 139-153.	1.1	41
17	A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. Human Molecular Genetics, 2015, 24, 5644-5654.	1.4	53
18	Lack of a Functioning P2X7 Receptor Leads to Increased Susceptibility to Toxoplasmic Ileitis. PLoS ONE, 2015, 10, e0129048.	1.1	27

#	Article	IF	Citations
19	A quantitative method for measuring innate phagocytosis by human monocytes using realâ€time flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 313-321.	1.1	24
20	Non-synonymous polymorphisms in the P2RX 4 are related to bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Purinergic Signalling, 2013, 9, 123-130.	1.1	15
21	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
22	Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary SjÃ¶gren's syndrome. Arthritis Research and Therapy, 2013, 15, R71.	1.6	17
23	A rare functional haplotype of theP2RX4andP2RX7genes leads to loss of innate phagocytosis and confers increased risk of ageâ€related macular degeneration. FASEB Journal, 2013, 27, 1479-1487.	0.2	61
24	Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. European Journal of Human Genetics, 2012, 20, 675-681.	1.4	63
25	P2X7 Receptor-mediated Scavenger Activity of Mononuclear Phagocytes toward Non-opsonized Particles and Apoptotic Cells Is Inhibited by Serum Glycoproteins but Remains Active in Cerebrospinal Fluid. Journal of Biological Chemistry, 2012, 287, 17318-17330.	1.6	23
26	Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. European Journal of Human Genetics, 2012, 20, 559-564.	1.4	63
27	A new role for the P2X7 receptor: a scavenger receptor for bacteria and apoptotic cells in the absence of serum and extracellular ATP. Purinergic Signalling, 2012, 8, 579-586.	1.1	39
28	The human P2X7 receptor and its role in innate immunity. Tissue Antigens, 2011, 78, 321-332.	1.0	172
29	Dysregulation of the inflammatory response to the parasite, Toxoplasma gondii, in P2X7 receptor-deficient mice. International Journal for Parasitology, 2011, 41, 301-308.	1.3	35
30	Genomeâ€wide metaâ€analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology, 2011, 70, 897-912.	2.8	314
31	P2X7 Is a Scavenger Receptor for Apoptotic Cells in the Absence of Its Ligand, Extracellular ATP. Journal of Immunology, 2011, 187, 2365-2375.	0.4	81
32	A Loss-of-Function Polymorphism in the Human P2X4 Receptor Is Associated With Increased Pulse Pressure. Hypertension, 2011, 58, 1086-1092.	1.3	52
33	The Role of the P2X7 Receptor in Infectious Diseases. PLoS Pathogens, 2011, 7, e1002212.	2.1	121
34	The P2X7-nonmuscle myosin membrane complex regulates phagocytosis of nonopsonized particles and bacteria by a pathway attenuated by extracellular ATP. Blood, 2010, 115, 1621-1631.	0.6	90
35	Identification of the promoter region of the P2RX4 gene. Molecular Biology Reports, 2010, 37, 3369-3376.	1.0	4
36	Functional significance of P2RX7 polymorphisms associated with affective mood disorders. Journal of Psychiatric Research, 2010, 44, 1116-1117.	1.5	14

#	Article	IF	Citations
37	Murine epidermal Langerhans cells and keratinocytes express functional P2X₇ receptors. Experimental Dermatology, 2010, 19, e151-7.	1.4	27
38	A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. PLoS ONE, 2010, 5, e13454.	1.1	55
39	Two haplotypes of the P2X₇receptor containing the Alaâ€348 to Thr polymorphism exhibit a gainâ€ofâ€function effect and enhanced interleukinâ€1Î² secretion. FASEB Journal, 2010, 24, 2916-2927.	0.2	155
40	P2X7 Receptor-Mediated Killing of an Intracellular Parasite,Toxoplasma gondii, by Human and Murine Macrophages. Journal of Immunology, 2010, 184, 7040-7046.	0.4	124
41	P2X7 receptor activation induces cell death and microparticle release in murine erythroleukemia cells. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 1797-1804.	1.4	38
42	TGF-Î²1 prevents up-regulation of the P2X7 receptor by IFN-Î³ and LPS in leukemic THP-1 monocytes. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 2058-2066.	1.4	25
43	Extracellular ATP dissociates nonmuscle myosin from P2X₇complex: this dissociation regulates P2X₇pore formation. American Journal of Physiology - Cell Physiology, 2009, 297, C430-C439.	2.1	79
44	Genetics of the P2X7 receptor and human disease. Purinergic Signalling, 2009, 5, 257-262.	1.1	114
45	Editorial. Purinergic Signalling, 2009, 5, 127-128.	1.1	0
46	The P2X7 receptor mediates the uptake of organic cations in canine erythrocytes and mononuclear leukocytes: comparison to equivalent human cell types. Purinergic Signalling, 2009, 5, 385-394.	1.1	24
47	Analysis of a large multiâ€generational family provides insight into the genetics of chronic lymphocytic leukemia. British Journal of Haematology, 2008, 142, 238-245.	1.2	26
48	Inhibition of the human P2X7 receptor by a novel protein tyrosine kinase antagonist. Biochemical and Biophysical Research Communications, 2008, 365, 515-520.	1.0	13
49	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood, 2008, 111, 5691-5693.	0.6	30
50	Canine erythrocytes express the P2X₇receptor: greatly increased function compared with human erythrocytes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R2090-R2098.	0.9	31
51	P2X7 receptor activation causes phosphatidylserine exposure in human erythrocytes. Biochemical and Biophysical Research Communications, 2007, 355, 169-173.	1.0	22
52	A Polymorphism in the P2X7Gene Increases Susceptibility to Extrapulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 360-366.	2.5	188
53	Rottlerin inhibits P2X 7 receptorâ€stimulated phospholipase D activity in chronic lymphocytic leukaemia Bâ€lymphocytes. Immunology and Cell Biology, 2007, 85, 68-72.	1.0	19
54	A quantitative method for routine measurement of cell surface P2X7 receptor function in leucocyte subsets by two-colour time-resolved flow cytometry. Journal of Immunological Methods, 2007, 325, 67-77.	0.6	27

#	Article	IF	Citations
55	Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood, 2006, 107, 2889-2894.	0.6	167
56	Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood, 2006, 107, 4946-4953.	0.6	149
57	Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 2006, 135, 184-197.	1.2	65
58	A Thr357 to Ser Polymorphism in Homozygous and Compound Heterozygous Subjects Causes Absent or Reduced P2X7 Function and Impairs ATP-induced Mycobacterial Killing by Macrophages. Journal of Biological Chemistry, 2006, 281, 2079-2086.	1.6	152
59	Purinoceptors are involved in the induction of an osmolyte permeability in malariaâ€infected and oxidized human erythrocytes. FASEB Journal, 2006, 20, 133-135.	0.2	69
60	From Budapest to Bar Harbor. Blood, 2005, 106, 1145-1146.	0.6	0
61	Human Epidermal and Monocyte-Derived Langerhans Cells Express Functional P2X7 Receptors. Journal of Investigative Dermatology, 2005, 125, 482-490.	0.3	45
62	Gene Dosage Determines the Negative Effects of Polymorphic Alleles of the P2X7Receptor on Adenosine Triphosphateâ€"Mediated Killing of Mycobacteria by Human Macrophages. Journal of Infectious Diseases, 2005, 192, 149-155.	1.9	64
63	A High-Density SNP Genomewide Linkage Scan for Chronic Lymphocytic Leukemiaâ€"Susceptibility Loci. American Journal of Human Genetics, 2005, 77, 420-429.	2.6	65
64	A 5â€² intronic splice site polymorphism leads to a null allele of the P2X7gene in 1-2% of the Caucasian population. FEBS Letters, 2005, 579, 2675-2678.	1.3	55
65	Strikingly Homologous Immunoglobulin Gene Rearrangements and Poor Outcome in VH3-21-Utilizing Chronic Lymphocytic Leukemia Independent of Geographical Origin and Mutational Status.. Blood, 2005, 106, 175-175.	0.6	6
66	An Arg307 to Gln Polymorphism within the ATP-binding Site Causes Loss of Function of the Human P2X7 Receptor. Journal of Biological Chemistry, 2004, 279, 31287-31295.	1.6	125
67	Glu496 to Ala Polymorphism in the P2X7 Receptor Impairs ATP-Induced IL-1Î² Release from Human Monocytes. Journal of Immunology, 2004, 172, 3399-3405.	0.4	140
68	Extracellular ATP Increases Cation Fluxes in Human Erythrocytes by Activation of the P2X7 Receptor. Journal of Biological Chemistry, 2004, 279, 44749-44755.	1.6	65
69	Association of the 1513C polymorphism in the P2X7 gene with familial forms of chronic lymphocytic leukaemia. British Journal of Haematology, 2004, 125, 815-817.	1.2	31
70	Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. British Journal of Pharmacology, 2004, 142, 1015-1019.	2.7	48
71	CXCR4 but not CXCR3 expression correlates with lymphocyte counts in B-cell chronic lymphocytic leukemia. Annals of Hematology, 2004, 83, 326-327.	0.8	7
72	Specific detection of non-functional human P2X7 receptors in HEK293 cells and B-lymphocytes. FEBS Letters, 2003, 538, 159-162.	1.3	26

#	Article	IF	Citations
73	P2X7 Receptor Cell Surface Expression and Cytolytic Pore Formation Are Regulated by a Distal C-terminal Region. Journal of Biological Chemistry, 2003, 278, 8853-8860.	1.6	153
74	An Ile-568 to Asn Polymorphism Prevents Normal Trafficking and Function of the Human P2X7 Receptor. Journal of Biological Chemistry, 2003, 278, 17108-17113.	1.6	154
75	A Loss-of-Function Polymorphism in the Human P2X7 Receptor Abolishes ATP-Mediated Killing of Mycobacteria. Journal of Immunology, 2003, 171, 5442-5446.	0.4	115
76	Extracellular adenosine 5'-triphosphate induces a loss of CD23 from human dendritic cells via activation of P2X7 receptors. International Immunology, 2002, 14, 1415-1421.	1.8	46
77	A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet, The, 2002, 359, 1114-1119.	6.3	145
78	The P2X7 receptor of CLL lymphocytes-a molecule with a split personality. Lancet, The, 2002, 360, 1898-1899.	6.3	18
79	Point mutations confer loss of ATP-induced human P2X7receptor function. FEBS Letters, 2002, 512, 43-46.	1.3	46
80	Impaired Transendothelial Migration of B-CLL Lymphocytes: a Defect Linked to Low L-Selectin Expression. Leukemia and Lymphoma, 2001, 42, 5-12.	0.6	20
81	Detection of P2X purinergic receptors on human B lymphocytes. Cell and Tissue Research, 2001, 304, 231-236.	1.5	70
82	Genetic polymorphisms of the human P2X7 receptor and relationship to function. Drug Development Research, 2001, 53, 72-76.	1.4	7
83	P2Y11 receptor expression by human lymphocytes: evidence for two cAMP-linked purinoceptors. European Journal of Pharmacology, 2001, 426, 157-163.	1.7	31
84	A Glu-496 to Ala Polymorphism Leads to Loss of Function of the Human P2X7 Receptor. Journal of Biological Chemistry, 2001, 276, 11135-11142.	1.6	276
85	Idiopathic thrombocytopenic purpura in adults. Medical Journal of Australia, 1999, 170, 196-197.	0.8	2
86	Transendothelial migration of lymphocytes in chronic lymphocytic leukaemia is impaired and involved down-regulation of both L-selectin and CD23. British Journal of Haematology, 1999, 105, 181-189.	1.2	33
87	Activation of the P2Z/P2X7Receptor in Human Lymphocytes Produces a Delayed Permeability Lesion: Involvement of Phospholipase D. Archives of Biochemistry and Biophysics, 1999, 362, 197-202.	1.4	36
88	Flow cytometric studies of nucleoside transport regulation in single chromaffin cells. FEBS Letters, 1998, 422, 368-372.	1.3	11
89	Seeking the nucleoside transporter. Nature Medicine, 1997, 3, 25-26.	15.2	8
90	The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. British Journal of Pharmacology, 1997, 120, 1483-1490.	2.7	174

#	Article	IF	Citations
91	ATP, a partial agonist for the P2Z receptor of human lymphocytes. British Journal of Pharmacology, 1997, 122, 911-917.	2.7	57
92	Phospholipase D activation by P2Z-purinoceptor agonists in human lymphocytes is dependent on bivalent cation influx. Biochemical Journal, 1996, 313, 529-535.	1.7	65
93	Extracellular ATP causes loss of L-selectin from human lymphocytes via occupancy of P2Z purinoceptors. , 1996, 166, 637-642.		92
94	Nucleoside transporters, bclâ€2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. European Journal of Haematology, 1996, 56, 213-220.	1.1	25
95	X-linked Pyridoxine-Responsive Sideroblastic Anemia Due to a Thr388-to-Ser Substitution in Erythroid 5-Aminolevulinate Synthase. New England Journal of Medicine, 1994, 330, 675-679.	13.9	122
96	The P_{2Z}â€purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP. British Journal of Pharmacology, 1994, 112, 946-950.	2.7	82
97	Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells. Cytometry, 1993, 14, 32-38.	1.8	28
98	The ATP4â^' receptor-operated ion channel of human lymphocytes: Inhibition of ion fluxes by amiloride analogs and by extracellular sodium ions. Archives of Biochemistry and Biophysics, 1992, 292, 411-418.	1.4	86
99	Transport of 2â€²-deoxycoformycin in human leukemie and lymphoma cells. Biochemical Pharmacology, 1991, 42, 708-710.	2.0	9
100	Treatment of acute promyelocytic leukaemia relapsing after allogeneic bone marrow transplantation with all-trans-retinoic acid: suppression of the leukaemic clone. British Journal of Haematology, 1991, 79, 331-334.	1.2	7
101	Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leukemia Research, 1990, 14, 475-479.	0.4	29
102	Immune thrombocytopenia association with oralgold treatment. Arthritis and Rheumatism, 1988, 31, 299-300.	6.7	5
103	Should we delete the digraphs (â€œaeâ€•and â€œoeâ€) from Australian medical writing?. Medical Journal of Australia, 1986, 144, 667-668.	0.8	1
104	Nucleoside transport and cytosine arabinoside (araC) metabolism in human T lymphoblasts resistant to araC, thymidine and 6-methylmecaptopurine riboside. European Journal of Cancer & Clinical Oncology, 1985, 21, 1077-1082.	0.9	13
105	Inherited red cell dehydration: a hemolytic syndrome in search of a name. Pathology, 1984, 16, 115-116.	0.3	8
106	Hereditary spherocytosis of man. Altered binding of cytoskeletal components to the erythrocyte membrane. Biochemical Journal, 1982, 201, 259-266.	1.7	25
107	Calcium ions, drug action and the red cell membrane. , 1982, 18, 271-292.		28
108	Molecular Stability of he Philly (Î±2Î²235 (C1) Tyr â†' Phe). Hemoglobin, 1981, 5, 177-190.	0.4	6

#	Article	IF	Citations
109	NORMAL FLUIDITY OF RED CELL MEMBRANES IN HEREDITARY SPHEROCYTOSIS. British Journal of Haematology, 1980, 46, 299-301.	1.2	13
110	Inhibition of cation contransport by cholesterol enrichment of human red cell membranes. Biochimica Et Biophysica Acta - Biomembranes, 1975, 413, 425-431.	1.4	101
111	A Furosemide-Sensitive Cotransport of Sodium plus Potassium in the Human Red Cell. Journal of Clinical Investigation, 1974, 53, 745-755.	3.9	228
112	An unusual variant of hereditary spherocytosis. American Journal of Medicine, 1970, 48, 63-71.	0.6	6
113	Red cell survival studies in hereditary spherocytosis. Journal of Clinical Investigation, 1970, 49, 666-672.	3.9	37